ALK and non-small cell lung carcinoma: There are approximately 10% to 15% of patients with non-small cell lung cancer (NSCLC) harboring MET amplification as a secondary driver of acquired resistance to targeted therapy including EGFR-TKIs or Anaplastic Lymphoma Kinase-Tyrosine Kinase Inhibitors (ALK-TKIs) (2, 3).